BTG3 and metabolic dysfunction-associated steatohepatitis: One recent study noted that ANA-positive MASLD patients had a higher prevalence of NASH at diagnosis; however, long-term outcomes, including hepatocellular carcinoma occurrence, extrahepatic malignancy, and overall survival, were similar to those of ANA-negative patients (31).